American Journal of Respiratory and Critical Care Medicine · 2023 · 16 citations · 19 references
MedicinePharmacologyPharmacotherapyInflammationMolecular PharmacologyPharmacodynamicsAcute InflammationAcute Lung InjuryAcute Respiratory Distress SyndromeAnti-inflammatory PharmacologyInflammation PharmacologyRespiratory DiseaseAcute Lung Injury PathophysiologyBacterial Pneumonia TreatmentCa2+ SignalingCalcium-mediated SignalingDruggable Target DiscoveryHalf-maximal Inhibitory ConcentrationPseudomonas Aeruginosa Pneumonia TreatmentStore-operated Calcium Entry
Abstract Rationale Acute respiratory distress syndrome (ARDS) has an unacceptably high mortality rate (35%) and is without effective therapy. Orai1 is a Ca2+ channel involved in store-operated Ca2+ entry (SOCE), a process that exquisitely regulates inflammation. Orai1 is considered a druggable target, but no Orai1-specific inhibitors exist to date. Objectives To evaluate whether ELD607, a first-in-class Orai1 antagonist, can treat ARDS caused by bacterial pneumonia in preclinical models. Methods ELD607 pharmacology was evaluated in HEK293T cells and freshly isolated immune cells from patients with ARDS. A murine acute lung injury model caused by bacterial pneumonia was then used: mice were infected with Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant S. aureus, or multidrug-resistant P. aeruginosa and then treated with ELD607 intranasally. Measurements and Main Results ELD607 specifically inhibited SOCE in HEK293T cells with a half-maximal inhibitory concentration of 9 nM. ELD607 was stable in ARDS airway secretions and inhibited SOCE in ARDS immune cells. In vivo, inhaled ELD607 significantly reduced neutrophilia and improved survival. Surprisingly, Orai1 inhibition by ELD607 caused a significant reduction in lung bacteria, including methicillin-resistant S. aureus. ELD607 worked as an immunomodulator that reduced cytokine levels, reduced neutrophilia, and promoted macrophage-mediated resolution of inflammation and clearance of bacteria. Indeed, when alveolar macrophages were depleted with inhaled clodronate, ELD607 was no longer able to resolve inflammation or clear bacteria. Conclusions These data indicate that specific Orai1 inhibition by ELD607 may be a novel approach to reduce multiorgan inflammation and treat antibiotic-resistant bacteria.
19
A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function
Stefan Feske, Yousang Gwack, Murali Prakriya et al. · Nature · 2006 · 2.3K citations
Crystal Structure of the Calcium Release–Activated Calcium Channel Orai
Xiaowei Hou, Leanne Pedi, Melinda M. Diver et al. · Science · 2012 · 558 citations
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis
Daniel Wendisch, Oliver Dietrich, Tommaso Mari et al. · Cell · 2021 · 543 citations · Full text
Jason C. Mercer, Wayne I. DeHaven, Jeremy T. Smyth et al. · Journal of Biological Chemistry · 2006 · 536 citations · Full text